Table 3 Characterization of study participants based on serum creatinine measurements during intensive phases of MDR-TB treatment at St.Peter’s Specialized Hospital and ALERT center, Addis Ababa, Ethiopia
Intensive phase of treatment (number of subjects on follow-up) | Serum creatinine (mg/dL) (Mean ± SEM) (95% CI) | Mean change of serum creatinine from baseline (%) | N(%) of participants with >50% increase of serum creatinine from baseline |
|---|---|---|---|
Baseline (n = 808) | 0.75 ± 0.02 [0.71–0.78] | – | – |
1st month (n = 769) | 0.82 ± 0.02 [0.78–0.87] | 2.9 | 83 (10.79) |
2nd month (n = 717) | 0.85 ± 0.02 [0.81–0.89] | 20.67 | 103 (14.36) |
3rd month (n = 661) | 0.84 ± 0.01 [0.81–0.88] | 13.3 | 105 (15.88) |
4th month (n = 619) | 0.86 ± 0.02 [0.81–0.91] | 75.6 | 101 (16.32) |
5th month (=582) | 0.86 ± 0.02 [0.82–0.91 | 1.9 | 90 (15.46) |
6th month (n = 533) | 0.84 ± 0.01 [0.81–0.88] | −33.4 | 84 (15.75) |
7th month (n = 482) | 0.82 ± 0.01 [0.80–0.85] | −47 | 76 (15.76) |
8th month (n = 415) | 0.83 + 0.01 [0.81–0.86] | −74.6 | 75 (18.07) |